STACEY BASQUIN: Open Payments
NPI 1760549919 · STATESBORO, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,316 in 161 payments from 26 companies in 2025. Trend: 2023 $1,574 · 2024 $2,465 · 2025 $3,316
Food & beverage: $2,837Consulting: $400Education: $79
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 22 | $446 |
| GlaxoSmithKline, LLC. | 28 | $427 |
| Avadel CNS Pharmaceuticals, LLC | 8 | $306 |
| Actelion Pharmaceuticals US, Inc. | 12 | $254 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $220 |
| Merck Sharp & Dohme LLC | 10 | $196 |
| Regeneron Healthcare Solutions, Inc. | 10 | $185 |
| Verona Pharma, Inc. | 8 | $172 |
| GENZYME CORPORATION | 7 | $148 |
| Insmed, Inc. | 16 | $146 |
Products named: DUPIXENT, LUMRYZ, TRELEGY ELLIPTA, Adempas, NUCALA, WINREVAIR, TEZSPIRE, Ohtuvayre.
Industry payments across GA — which companies pay providers there.
